How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

33,593 results for

Adverse Drug Reaction

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system. (PubMed)

Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system. A new method to assess causality of suspected adverse drug reactions, the Liverpool Adverse Drug Reaction Causality Assessment Tool (LCAT), showed high interrater agreement when used by its developers. Our aim was to compare the interrater agreement achieved (...) by LCAT to that achieved by another causality assessment method, the World Health Organization-Uppsala Monitoring Centre system for standardised case causality assessment (WHO-UMC system), in our setting.Four raters independently assessed adverse drug reaction causality of 48 drug-event pairs, identified during a hospital-based survey. A randomised design ensured that no washout period was required between assessments with the two methods. We compared the methods' interrater agreement by calculating

Full Text available with Trip Pro

2017 PLoS ONE

2. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. (PubMed)

Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database. Attention deficit/hyperactivity disorder (ADHD) can be comorbid with frequent anxiety and mood disorders, as well as emotional symptoms (anxiety, irritability, mood lability). These may also be triggered by drugs and appear as adverse drug reactions (ADRs).We mined (...) data from the US Food and Drug Administration Adverse Event Reporting System pharmacovigilance database, focused on methylphenidate, atomoxetine, amphetamine, lisdexamfetamine, and their derivatives. We collected reports of ADRs connected with mood or emotional symptoms in pediatric patients, excluding drug abuse/accidents. Reporting odds ratios (RORs) were calculated and compared between drug classes and children/adolescents.We collected 6176 ADRs of interest of which 59% occurred in children

2019 Journal of Clinical Psychopharmacology

3. Efficacy of acupressure to prevent adverse reactions to anti-tuberculosis drugs: Randomized controlled trials

Efficacy of acupressure to prevent adverse reactions to anti-tuberculosis drugs: Randomized controlled trials To determine whether acupressure can prevent or relieve the adverse drug reactions (ADRs) of anti-tuberculosis drugs.People receiving drug treatment for TB often experience ADRs that may cause them to stop taking their medication. Acupressure is a form of traditional Chinese medicine that can be applied to alleviate or prevent disease symptoms.A double-blinded, repeated-measures (...) . Outcomes (gastrointestinal irritation and adverse skin reactions) were assessed according to the people feedback and the physicians' recordings during the treatment course, and during monthly follow-up visits for 6 months thereafter.Both groups typically experienced gastrointestinal irritation and adverse skin reactions within 2 months of beginning anti-tuberculosis drug treatment. The 4-weeks intervention involving relevant acupressure points successfully relieved both types of side effects in both

2019 EvidenceUpdates

4. Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologic (PubMed)

Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologic Naturally occurring botulism is rare, but a large number of cases could result from unintentional or intentional contamination of a commercial food. Despeciated, equine-derived, heptavalent botulinum antitoxin (HBAT) is licensed in the United (...) States. Timely treatment reduces morbidity and mortality, but concerns that botulinum antitoxin can induce anaphylaxis exist. We sought to quantify the allergy risk of botulinum antitoxin treatment and the usefulness of skin testing to assess this risk.We conducted a systematic review of (1) allergic reactions to botulinum antitoxin and (2) the predictive value of skin testing (ST) before botulinum antitoxin administration. We searched 5 scientific literature databases, reviewed articles' references

Full Text available with Trip Pro

2017 Clinical Infectious Diseases

5. Adverse Drug reactions in an Ageing PopulaTion (ADAPT) study protocol: a cross-sectional and prospective cohort study of hospital admissions related to adverse drug reactions in older patients. (PubMed)

Adverse Drug reactions in an Ageing PopulaTion (ADAPT) study protocol: a cross-sectional and prospective cohort study of hospital admissions related to adverse drug reactions in older patients. Older people experience greater morbidity with a corresponding increase in medication use resulting in a potentially higher risk of adverse drug reactions (ADRs). The aim of this study is to determine the prevalence and characteristics of ADR-related hospital admissions among older patients (≥65 years

Full Text available with Trip Pro

2017 BMJ open

6. The effect of SENATOR (Software ENgine for the Assessment and optimisation of drug and non-drug Therapy in Older peRsons) on incident adverse drug reactions (ADRs) in an older hospital cohort - Trial Protocol. (PubMed)

The effect of SENATOR (Software ENgine for the Assessment and optimisation of drug and non-drug Therapy in Older peRsons) on incident adverse drug reactions (ADRs) in an older hospital cohort - Trial Protocol. The aim of this trial is to evaluate the effect of SENATOR software on incident, adverse drug reactions (ADRs) in older, multimorbid, hospitalized patients. The SENATOR software produces a report designed to optimize older patients' current prescriptions by applying the published STOPP (...) and START criteria, highlighting drug-drug and drug-disease interactions and providing non-pharmacological recommendations aimed at reducing the risk of incident delirium.We will conduct a multinational, pragmatic, parallel arm Prospective Randomized Open-label, Blinded Endpoint (PROBE) controlled trial. Patients with acute illnesses are screened for recruitment within 48 h of arrival to hospital and enrolled if they meet the relevant entry criteria. Participants' medical history, current prescriptions

Full Text available with Trip Pro

2019 BMC Geriatrics

7. Adverse drug reactions caused by drug-drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. (PubMed)

Adverse drug reactions caused by drug-drug interactions in cardiovascular disease patients: introduction of a simple prediction tool using electronic screening database items. Objective: Cardiovascular disease (CVD) drugs have been frequently implicated in adverse drug reaction (ADR)-related hospitalizations. Drug-drug interactions (DDIs) are common preventable cause of ADRs, but the impact of DDIs in the CVD population has not been investigated. Hence, the primary aim of the study (...) was to identify DDIs associated with ADRs in CVD patients at hospital admission. The second aim was to develop a simple tool to identify high-risk patients for DDI-related adverse events. Methods: An observational study was conducted on the Cardiology Ward of University Clinical Hospital Center. Data were obtained from medical charts. A clinical panel identified DDIs implicated in ADRs, using LexiInteract database and Drug Interaction Probability Scale. Statistics were performed using PASW 22 (SPSS Inc

2019 Current medical research and opinion

8. ADRIC: Adverse Drug Reactions In Children - a programme of research using mixed methods

ADRIC: Adverse Drug Reactions In Children - a programme of research using mixed methods ADRIC - Adverse Drug Reactions in Children Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata

Full Text available with Trip Pro

2014 NIHR HTA programme

9. Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: The Japan Adverse Drug Events Study (PubMed)

Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: The Japan Adverse Drug Events Study It is difficult to determine adverse drug reactions (ADRs) in daily complicated clinical practice in which many kinds of drugs are prescribed. We evaluated how well the Naranjo Algorithm (NA) categorized ADRs among suspected ADRs. The Japan Adverse Drug Events (JADE) study was a prospective cohort study of 3459 inpatients. After all suspected ADRs were reported

Full Text available with Trip Pro

2018 Pharmacology research & perspectives

10. Look-alike and sound-alike drugs: A potential cause of cutaneous adverse reactions to drugs. (PubMed)

Look-alike and sound-alike drugs: A potential cause of cutaneous adverse reactions to drugs. Cutaneous adverse drug reactions (CADRs) are the most frequent adverse reactions to drugs, with incidence ranging from 1% to 3%. Severe cutaneous adverse reactions (SCARs) to drugs are associated with mortality and drug-development challenges.1 A contributor to dispensing errors are look-alike and sound-alike (LASA) drug names. This article is protected by copyright. All rights reserved.This article

2019 British Journal of Dermatology

11. Correction: Machine learning model combining features from algorithms with different analytical methodologies to detect laboratory-event-related adverse drug reaction signals. (PubMed)

Correction: Machine learning model combining features from algorithms with different analytical methodologies to detect laboratory-event-related adverse drug reaction signals. [This corrects the article DOI: 10.1371/journal.pone.0207749.].

Full Text available with Trip Pro

2019 PLoS ONE

12. Meta-analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults

Meta-analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults To examine the effect of interventions to optimize medication use on adverse drug reactions (ADRs) in older adults.Systematic review and meta-analysis. EMBASE, PubMed, OVID, Cochrane Library, Clinicaltrials.gov, and Google Scholar were searched through April 30, 2017.Randomized controlled trials.Older adults (mean age ≥65) taking medications.Two authors independently extracted relevant information and assessed

2018 EvidenceUpdates

13. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir with Once-Weekly Isoniazid and Rifapentine. (PubMed)

Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir with Once-Weekly Isoniazid and Rifapentine. Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection. This study aimed to examine pharmacokinetic drug-drug interactions between this regimen and dolutegravir, a first-line antiretroviral medication.This was a single-center, open-label, fixed-sequence, drug (...) -drug interaction study in healthy volunteers. Subjects received oral dolutegravir 50 mg once daily alone (days 1-4) and concomitantly with once-weekly isoniazid 900 mg, rifapentine 900 mg, and pyridoxine 50 mg (days 5-19). Dolutegravir concentrations were measured on days 4, 14, and 19, and rifapentine, 25-desacetyl-rifapentine, and isoniazid concentrations were measured on day 19. Cytokines and antidrug antibodies to isoniazid and rifapentine were examined at select time points.The study

Full Text available with Trip Pro

2018 Clinical Infectious Diseases

14. Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting (PubMed)

Pharmacovigilance: pharmacists’ perspective on spontaneous adverse drug reaction reporting Globally, adverse drug reactions (ADRs), one of the leading causes of morbidity and mortality, will continue to pose a threat to public health as long as drugs are being used to treat various ailments. Prompt ADR reporting is crucial in ensuring drug safety. The aim of this narrative review was to highlight the role of pharmacists in pharmacovigilance and to identify barriers and facilitators toward ADR

Full Text available with Trip Pro

2017 Integrated pharmacy research & practice

15. Interventions to reduce adverse drug reactions following hospitalisation - a systematic review

Interventions to reduce adverse drug reactions following hospitalisation - a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external (...) characteristics (e.g. species, sex or drug class or dose) and effect size. They should be considered hypothesis-generating. Ideally, a threshold describing the number of studies per subgroup required for analysis should be specified. For further guidance please refer to the and to pre-clinical meta-analysis. Example: The following study characteristics will be examined as potential source of heterogeneity: species (stratified per species); sex (stratified per sex); duration of index ischemia (linear); stem

2019 PROSPERO

16. Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients (PubMed)

Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients Based on data of clinical trials, new agents are receiving approval to the pharmaceutical market, for which information concerning safety issues under real-life conditions is not yet available.The aim was to evaluate the tolerability of newer antiepileptic drugs (AEDs), such as topiramate, levetiracetam, zonisamide, pregabalin, extended-release oxcarbazepine (...) , lacosamide and eslicarbazepine, under real-life conditions by means of an assessment of routine clinical data of inpatients.Over 2.75 years data of all inpatients receiving one of the newer AEDs were documented. Occurring adverse drug reactions (ADRs) were classified according to the WHO-UMC Causality Assessment concerning their likely relationship to the prescribed AEDs. For each AED, the total number of patients without and with ADRs, assessed as at least possibly related to the particular drug

Full Text available with Trip Pro

2016 Drugs - real world outcomes

17. Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older

Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those (...) 60 years and older We have recently received 2 reports of fatal adverse reactions to the yellow fever vaccine (Stamaril). Due to an increased risk of life-threatening reactions, the vaccine must not be given to anyone with a medical history of thymus dysfunction or who is immunosuppressed. In addition, extreme caution must be used and a careful risk assessment conducted before vaccination of people aged 60 years and older due to a substantially increased risk of such adverse reactions in this age

2019 MHRA Drug Safety Update

18. Naltrexone/bupropion (Mysimba): risk of adverse reactions that could affect ability to drive

reactions, a new warning has been added to the product information that naltrexone/bupropion may affect the ability to drive, operate machinery, or perform dangerous tasks. In a few cases, loss of consciousness occurred when the patient was driving, including a small number of cases worldwide associated with a road traffic accident. As of publication of this article, no adverse drug reaction reports for naltrexone/bupropion received through the UK Yellow Card Scheme have indicated a road traffic (...) affect their driving ability, for example if a recent loss of consciousness or seizure is suspected. In England and Wales, it is also illegal to drive with blood concentrations of certain controlled drugs above pre-specified limits. See for more information. Report suspected adverse drug reactions via the Yellow Card Scheme Please continue to report any suspected adverse drug reaction via the . Remember only a suspicion is needed to report – if in doubt, please complete a Yellow Card. Healthcare

2019 MHRA Drug Safety Update

19. Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements

or imaging features. Lemtrada is a monoclonal antibody that binds to CD52. Report any suspected adverse drug reactions on a Yellow Card Healthcare professionals and patients should continue to report any suspected adverse drug reactions to alemtuzumab to the . Further information Direct Healthcare Professional Communication. . April 2019. EMA announcement. . 12 April 2019 Article citation: Drug Safety Update volume 12, issue 10: May 2019: 1. Data derived from IQVIA IMS MIDAS, 01/2014-12/2018 (...) Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use

Full Text available with Trip Pro

2019 MHRA Drug Safety Update

20. Pharmacogenetic testing to identify the risk of adverse reactions to anti-epileptic medications.

of human leukocyte antigen (HLA) testing to determine whether carbamazepine treatment should be prescribed. However, expert opinion suggests that carbamazepine is no longer offered as first-line treatment and people with newly diagnosed epilepsy are instead offered a drug with a lower rate of adverse drug reactions. As such, this testing approach may be of limited applicability to current practice. The HTW Assessment Group concluded that informed guidance could not be made at this time. Why (...) Pharmacogenetic testing to identify the risk of adverse reactions to anti-epileptic medications. Pharmacogenetic testing - Health Technology Wales > Pharmacogenetic testing Pharmacogenetic testing Topic Status Complete Pharmacogenetic testing to identify the risk of adverse reactions to anti-epileptic medications. Outcome The evidence on the use of pharmacogenetics testing to identify the risk of adverse reactions to anti-epileptic medications is limited. Some evidence was identified on the use

2019 Health Technology Wales

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>